Novartis terminates collaboration with Pliant; discontinues NASH program PLN-1474

PLIANT THERAPEUTICS, INC.

Novartis notified Pliant on Feb 17, 2023 of termination of Collaboration and License Agreement, effective April 18, 2023.
Novartis is divesting clinical NASH assets and discontinuing development of PLN-1474 (integrin αvβ1 inhibitor for liver fibrosis).
Pliant had received $50M upfront and $29M in contingent payments; up to $416M in future milestones and royalties now terminated.
All rights and licenses, including PLN-1474 and validated research target compounds, revert to Pliant.
Research term for up to three additional integrin targets concludes Q1 2023; one target validated with multiple development candidates.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.